PULSENMORE LTD
PLSMNASDAQTrading Snapshot
- Day Range
- $2.16 – $2.23
- 52-Week Range
- $2.22 – $12.97
- Volume
- $1.83B
- Avg Volume
- $1.59B
- Shares Outstanding
- 6.5M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $40M
- Last Q Revenue
- $6M
- P/E Ratio
- -1.0
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-7.05
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.5%
Why Investors Own PLSM
- ✓High-growth profile — revenue up +53.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PULSENMORE LTD
PLSM
StockOtter · stockotter.spaceAbout PULSENMORE LTD
Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Pulsenmore Expands Its Fertility Platform into the UK
MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform into the UK fertility market where more than 100,000 IVF and fertilit
Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring
The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home This registration marks the Company's second product authorized in Eur
Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026
Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update OMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote materna
Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026
OMER, Israel, Aug. 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, today announces that it will release its fin
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring
The Company's home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov, expanding the ability to incorporate at-home ultrasound scans as part of pregnancy monitoring RAMAT GAN, Israe
Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program
The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of approximately $3.12 million. The program is designed to